WO2008057253A3 - Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles - Google Patents

Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles Download PDF

Info

Publication number
WO2008057253A3
WO2008057253A3 PCT/US2007/022649 US2007022649W WO2008057253A3 WO 2008057253 A3 WO2008057253 A3 WO 2008057253A3 US 2007022649 W US2007022649 W US 2007022649W WO 2008057253 A3 WO2008057253 A3 WO 2008057253A3
Authority
WO
WIPO (PCT)
Prior art keywords
diindolylmethane
related indoles
parasitic
methods
compositions utilizing
Prior art date
Application number
PCT/US2007/022649
Other languages
French (fr)
Other versions
WO2008057253A2 (en
Inventor
Michael A Zeligs
Original Assignee
Bioresponse Llc
Michael A Zeligs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioresponse Llc, Michael A Zeligs filed Critical Bioresponse Llc
Priority to BRPI0717753-4A priority Critical patent/BRPI0717753B1/en
Priority to US12/447,307 priority patent/US8586621B2/en
Publication of WO2008057253A2 publication Critical patent/WO2008057253A2/en
Publication of WO2008057253A3 publication Critical patent/WO2008057253A3/en
Priority to US14/051,248 priority patent/US9353058B2/en
Priority to US14/975,118 priority patent/US9663462B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis.
PCT/US2007/022649 2006-10-27 2007-10-26 Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles WO2008057253A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BRPI0717753-4A BRPI0717753B1 (en) 2006-10-27 2007-10-26 Use of a composition comprising 50-250 mg of one or more dim-related indoles and one or more anti-protozoal agents, and, composition
US12/447,307 US8586621B2 (en) 2006-10-27 2007-10-26 Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
US14/051,248 US9353058B2 (en) 2006-10-27 2013-10-10 Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
US14/975,118 US9663462B2 (en) 2006-10-27 2015-12-18 Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85483006P 2006-10-27 2006-10-27
US60/854,830 2006-10-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/447,307 A-371-Of-International US8586621B2 (en) 2006-10-27 2007-10-26 Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
US14/051,248 Division US9353058B2 (en) 2006-10-27 2013-10-10 Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles

Publications (2)

Publication Number Publication Date
WO2008057253A2 WO2008057253A2 (en) 2008-05-15
WO2008057253A3 true WO2008057253A3 (en) 2008-11-27

Family

ID=39364993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/022649 WO2008057253A2 (en) 2006-10-27 2007-10-26 Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles

Country Status (5)

Country Link
US (3) US8586621B2 (en)
BR (1) BRPI0717753B1 (en)
CO (1) CO6190514A2 (en)
EC (1) ECSP099364A (en)
WO (1) WO2008057253A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057253A2 (en) 2006-10-27 2008-05-15 Bioresponse, L.L.C. Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
CN101623255B (en) * 2008-07-08 2010-12-29 中国农业科学院兰州畜牧与兽药研究所 Artesunate nanoemulsion drug composition and preparation method thereof
JP5477731B2 (en) * 2008-07-10 2014-04-23 日本ゼトック株式会社 Melanin inhibitor, whitening agent, collagenase inhibitor, skin preparation, oral composition and food
EP2326327B1 (en) 2008-09-17 2016-03-23 SRI International Analogs of indole-3-carbinol and their use as agents against infection
TWI384995B (en) * 2008-12-05 2013-02-11 Univ Taipei Medical Type i topoisomerase inhibitor
FR2958118B1 (en) * 2010-04-01 2012-06-15 Pancosma Sa Pour L Ind Des Produits Biochimiques USE OF AT LEAST ONE DIALKYL THIOSULFINATE OR THIOSULFONATE FOR REDUCING THE NUMBER OF APICOMPLEXES IN A MONOGASTRIC ANIMAL
CN102552458A (en) * 2010-12-16 2012-07-11 天津中敖生物科技有限公司 Chinese medicine composition for treating chicken coccidiosis and preparation method thereof
ES2388963B1 (en) * 2011-03-24 2013-09-13 Univ Navarra DEVELOPMENT AND USE OF LIPID NANOPARTICLES CONTAINING EDELPHOSINE AND OTHER ETHERS OF PHOSPHOLIPIDS IN ANTITUMORAL AND ANTIPARASITARY THERAPY
GB201105050D0 (en) * 2011-03-25 2011-05-11 Iiaa Ltd Pharmaceutical agent
EP2561868A1 (en) * 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
GB2533381A (en) * 2014-12-18 2016-06-22 Nordic Labs Ltd Novel treatment of STIs
FR3034095A1 (en) * 2015-03-26 2016-09-30 Agronomique Inst Nat Rech PREVENTING AND / OR TREATING PARASITOSES INDUCED BY PARASITES BELONGING TO THE PHYLUM OF APICOMPLEXES
GB2542106A (en) * 2015-04-01 2017-03-15 Nordic Labs Ltd Novel treatment of STIs
AU2016245984B2 (en) 2015-04-10 2021-03-25 Bioresponse, L.L.C. Self-emulsifying formulations of DIM-related indoles
CN105311007B (en) * 2015-11-12 2017-10-10 广东省农业科学院动物卫生研究所 Application of the naganol in anticoccidial drugs thing is prepared
US20200179337A1 (en) * 2016-05-16 2020-06-11 Aktsionernoe Obschestvo "Veles Farma" Means for treating sexually transmitted infections
CN106309459A (en) * 2016-08-18 2017-01-11 天承南运(天津)科技有限公司 Application of paromomycin sulfate in preparation of neutrophil inhibitor
CN110446505A (en) * 2017-01-20 2019-11-12 皮肤科技生命科学有限公司 For treating dermopathic conjoint therapy
CN110496121A (en) * 2019-08-23 2019-11-26 西南大学 Dihydroqinghaosu resists the application in leishmanial drug in preparation
WO2023215819A2 (en) * 2022-05-06 2023-11-09 Whitehead Institute For Biomedical Research Antiparasitic agents and methods
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100264A1 (en) * 2004-11-06 2006-05-11 Bjeldanes Leonard F 3,3'-Diindolylmethane immune activating compositions
WO2006053160A2 (en) * 2004-11-12 2006-05-18 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718921A (en) * 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
FR2676927B1 (en) * 1991-05-29 1995-06-23 Ibf MICROSPHERES FOR USE IN THERAPEUTIC VASCULAR OCCLUSIONS AND INJECTABLE SOLUTIONS CONTAINING THEM.
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
AU683838B2 (en) * 1992-05-19 1997-11-27 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
WO1996030347A1 (en) 1995-03-30 1996-10-03 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CZ1598A3 (en) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidines and process for preparing thereof
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (en) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 Irreversible inhibitor of tyrosine kinase
US5948808A (en) * 1997-03-07 1999-09-07 The Texas A&M University System Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
AU6564798A (en) * 1997-03-18 1998-10-12 Brigham And Women's Hospital Methods and kits for treating and diagnosing leiomyomas
US6150395A (en) * 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
US5895787A (en) * 1997-10-08 1999-04-20 Designed Nutritional Products, Inc. Treatment of fibromyalgia and related disorders
US6086915A (en) * 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
BR9910025A (en) 1998-04-29 2000-12-26 Pfizer Prod Inc N- (3-Ethinylphenylamino) -6,7-bis (2-methoxyethoxy) -4-quinazo linamine dehydrated and monohydrated mesylate
DE69920455T2 (en) 1998-07-08 2005-01-20 Harbor Branch Oceanographic Institution Inc., Fort Pierce BIS-INDOLEDERIVATE AND ITS USE AS AN INFLAMMATORY AGENT
GEP20032997B (en) 1998-11-19 2003-06-25 Warner Lambert Co N-[4-(3-Chloro-4-Fluoro-Phenylamino)-7-(3-Morpholin-4-Yl-Propoxy)-Quinazolin-6-Yl]-crylamide, as an Irreversible Inhibitor of Tyrosine Kinases
US6875584B1 (en) * 1999-03-02 2005-04-05 University Of Georgia Research Foundation, Inc. Prophylactic and therapeutic immunization against protozoan infection and disease
US6613792B1 (en) * 1999-08-02 2003-09-02 Designed Nutritional Products, Inc. Treatment of premenstrual syndrome and menopause
US7384971B2 (en) * 1999-09-23 2008-06-10 Bioresponse L.L.C. Phytochemicals for the treatment of cervical dysplasia
US6534085B1 (en) * 1999-09-23 2003-03-18 Bioresponse L.L.C. Phytochemicals for promoting weight loss
US6689387B1 (en) * 1999-09-23 2004-02-10 Bioresponse Llc Phytochemicals for treatment of mastalgia and endometriosis
JP4871476B2 (en) * 2000-03-13 2012-02-08 バイオコンパティブルズ ユーケー リミテッド Embolization composition
US6399645B1 (en) * 2000-03-20 2002-06-04 Maria Bell Chemoprevention and treatment of cervical or vaginal neoplasia
WO2001072281A2 (en) * 2000-03-24 2001-10-04 Biosphere Medical Inc. Microspheres for active embolization
US6477229B1 (en) * 2000-05-12 2002-11-05 Siemens Medical Solutions Usa, Inc. Radiation therapy planning
US7709520B2 (en) * 2000-10-06 2010-05-04 The Texas A&M University System Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
US20020147155A1 (en) * 2001-04-06 2002-10-10 Foster Warren G. Prevention and treatment of endometriosis with aryl hydrocarbon receptor binding ligands
ATE354355T1 (en) * 2001-04-27 2007-03-15 Ajinomoto Kk A DISPERSION OF HIGHLY FINE PARTICLES CONTAINING BETA-GLUCAN, A CORRESPONDING PRODUCTION PROCESS AND THE USE OF THE DISPERSION
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
US7348352B2 (en) * 2001-10-23 2008-03-25 Bioresponse L.L.C. Diindolylmethane for the treatment of HPV infection
CA2480128A1 (en) * 2002-03-26 2003-10-09 Immunex Corporation Methods of using flt3-ligand in immunization protocols
US20030220377A1 (en) * 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
US6800655B2 (en) * 2002-08-20 2004-10-05 Sri International Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
US9668972B2 (en) * 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
WO2004071425A2 (en) 2003-02-06 2004-08-26 Bioresponse, Llc The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions
WO2005003160A1 (en) * 2003-07-01 2005-01-13 Vib Vzw Actin mutants
CA2565721C (en) 2004-05-06 2015-10-06 Bioresponse, L.L.C. Diindolymethane formulations for the treatment of leiomyomas
US20060111423A1 (en) 2004-10-26 2006-05-25 Zeligs Michael A Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
WO2006083458A2 (en) * 2004-12-30 2006-08-10 Bioresponse Llc Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
US20060229355A1 (en) * 2005-04-08 2006-10-12 The Regents Of The University Of California 3.3'-Diindolylmethane compositions inhibit angiogenesis
WO2008057253A2 (en) 2006-10-27 2008-05-15 Bioresponse, L.L.C. Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100264A1 (en) * 2004-11-06 2006-05-11 Bjeldanes Leonard F 3,3'-Diindolylmethane immune activating compositions
WO2006053160A2 (en) * 2004-11-12 2006-05-18 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases

Also Published As

Publication number Publication date
US20160101083A1 (en) 2016-04-14
US9663462B2 (en) 2017-05-30
ECSP099364A (en) 2009-07-31
BRPI0717753B1 (en) 2022-04-12
US9353058B2 (en) 2016-05-31
US8586621B2 (en) 2013-11-19
US20100055201A1 (en) 2010-03-04
CO6190514A2 (en) 2010-08-19
BRPI0717753A2 (en) 2013-10-22
US20140037577A1 (en) 2014-02-06
WO2008057253A2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2008057253A3 (en) Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
WO2010042163A3 (en) Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
EA200901032A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
MX2009007944A (en) Compounds and compositions as kinase inhibitors.
MY186986A (en) Compositions and methods of use of phorbol esters
WO2008033562A3 (en) Kinase inhibitor compounds
MA32393B1 (en) Compounds and compounds that act as kinase inhibitors
EA201391720A1 (en) SUBSTITUTED DIOXOPIPERIDINYL-PHTHALIMIDE DERIVATIVES
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (en) Compounds and compositions as modulators of gpr119 activity
MY157860A (en) Prevention and treatment of secondary infections following viral infection
MX2020004099A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same.
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
GEP20135925B (en) Inhibitors of hedgehog pathway
EA201290191A1 (en) N1-PYRAZOLOSPIROKETONE INHIBITORS ACETYL-KoA-CARBOXYLASE
EA200700909A1 (en) AZAINDOLKARBOXAMIDES
EA201170834A1 (en) CONNECTIONS SUITABLE FOR INHIBITING CHK1
EA201170963A1 (en) POLY INHIBITORS (ADP-Ribose) POLYMERASE (PARP)
EA201001847A1 (en) COMPOUNDS AND COMPOSITIONS APPLICABLE FOR THE TREATMENT OF MALARIA
WO2007092065A3 (en) Compounds and compositions as lxr modulators
EA201100138A1 (en) 4-PHENOXYMETHYL-PIPERIDINES AS MODEL ACTIVITY GPR119
EA201071231A1 (en) CARBOXAMIDE CONNECTIONS FOR THE TREATMENT OF METABOLIC DEVICES
EA201400358A1 (en) SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTAN-3-CARBOXAMIDE INHIBITORS KATEPSIN C
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
EA201390353A1 (en) DERIVATIVE PYRAZOLOHINOLINA

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07839788

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12447307

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2804/CHENP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 09054148

Country of ref document: CO

122 Ep: pct application non-entry in european phase

Ref document number: 07839788

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0717753

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090427